Date: 2013-10-17
Type of information: Collaboration agreement
Compound:
Company: AstraZeneca (UK) National Research Program for Biopharmaceuticals (NRPB) (Taiwan)
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Respiratory diseases - Inflammatory diseases - Autoimmune diseases - Cancer - Oncology - Infectious diseases - CNS diseases.
Type agreement: collaboration
R&D
Action mechanism:
Disease:
Details: * On October 17, 2013, AstraZeneca and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) have announced a collaborative programme to support academic research proposals using ‘open innovation’ as a catalyst for drug discovery. The programme will connect expert physicians and scientists with a wide range of high-quality, small molecule compounds and biologics developed by AstraZeneca. Successful research proposals submitted from academic institutes in Taiwan will be funded by the NRPB to explore new therapeutic uses for specific AstraZeneca compounds which may in turn lead to the development of novel therapies for patients. Further financial details were not disclosed. Areas of high interest include cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Some medical compounds do not prove effective for the specific use for which they were developed. However, if additional research is conducted, they may succeed for different therapeutic uses. Also, some medical compounds with existing, proven benefits may also be found to have additional and sometimes unrelated uses after further research. This agreement provides a framework that will enable researchers to access a defined collection of AstraZeneca candidate drugs and their related data to enable such additional pre-clinical and clinical studies.
The collaboration also brings together complementary skills that will help researchers harness and foster medical innovation: NRPB’s and academic thought-leaders’ insights that will propose and accelerate the investigation of innovative hypotheses and technologies; AstraZeneca via its proven track record in global research and drug discovery.
Financial terms:
Latest news:
